AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28793888 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (eyes open)
Number of subjects: 38
Study 28793946 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs
Number of subjects: 227
Study 28793994 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Unsaturated Fatty Acids (UFAs)
Number of subjects: 4146
Study 28793994 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids (PUFAs)
Number of subjects: 4146
Study 28793994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis Monounsaturated Fatty Acids (MUFAs)
Number of subjects: 4146
Study 28794078 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4 (50 mg weekly subcutaneous administration)
Number of subjects: 245
Study 28794078 — intervention group
Group type: COMPARATOR
Intervention: ETN (50 mg weekly subcutaneous administration)
Number of subjects: 245
Study 28794078 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4 (SB4/SB4)
Number of subjects: 245
Study 28794078 — intervention group
Group type: COMPARATOR
Intervention: ETN (ETN/SB4)
Number of subjects: 245
Study 28794136 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum neutrophil gelatinase-associated lipocalin (sNGAL) levels in the last tertile (>220 ng/L)
Number of subjects: 1371
Study 28794136 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative acute kidney injury (AKI) defined using the International Kidney Disease: Improving Global Outcomes classification
Number of subjects: 1371
Study 28794139 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator for primary prevention of sudden cardiac arrest
Number of subjects: 204
Study 28794139 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater volume of denervated myocardium (defect of the positron emission tomography norepinephrine analog)
Number of subjects: 204
Study 28794175 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28794208 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing amounts of chicken intake (from 88 to 290 g/d) over 3 weeks
Number of subjects: 10
Study 28794208 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumers of chicken (based on National Adult Nutrition Survey)
Number of subjects: 10
Study 28794208 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported chicken intake
Number of subjects: 10
Study 28794208 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma metabolite analysis
Number of subjects: 10
Study 28794257 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for mutations using a high-coverage ataxia-specific gene panel and next-generation sequencing
Number of subjects: 249
Study 28794257 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 249
Study 28794888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried foods ≥5 servings/week
Number of subjects: 888
Study 28794888 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda intake
Number of subjects: 888
Study 28794898 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 1318
Study 28794898 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 1318
Study 28794898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination pill
Number of subjects: 1318
Study 28794898 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident hypertensive patients
Number of subjects: 1318
Study 28794898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive patients
Number of subjects: 1318
Study 28795156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted brace casting (US group)
Number of subjects: 34
Study 28795156 — intervention group
Group type: COMPARATOR
Intervention: Control group (Providence brace design system)
Number of subjects: 34
Study 28795383 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Imaginative Distention (IID) therapy, delivered as eight weekly training group sessions by a skilled psychotherapist.
Number of subjects: 144
Study 28795383 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 144
Study 28795890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence image-guided curettage or biopsy sampling
Number of subjects: 60
Study 28796275 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature platelets (IPF) measured postoperatively in the PACU
Number of subjects: 732
Study 28796275 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut off of IPF > 5.4%
Number of subjects: 732
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis 4 index (FIB-4)
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: BARD
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD fibrosis score (NFS)
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFI
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 315
Study 28796410 — intervention group
Group type: EXPERIMENTAL
Intervention: NFS
Number of subjects: 315
Study 28796812 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102 (Ad5/3-D24-GM-CSF) administered by intracardial, intraperitoneal or subcutaneous injections
Number of subjects: 300
Study 28796812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide administered intraperitoneally twice a week
Number of subjects: 300
Study 28796812 — intervention group
Group type: COMPARATOR
Intervention: NaCl solution administered to control group
Number of subjects: 300
Study 28796864 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized adaptive stereotactic body radiotherapy (SBRT)
Number of subjects: 90
Study 28797193 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (800-1200 mg)
Number of subjects: 106
Study 28797263 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) with sulfadoxine + amodiaquine (SP + AQ)
Number of subjects: 15
Study 28797263 — intervention group
Group type: COMPARATOR
Intervention: Comparison district (Bafoulabe)
Number of subjects: 15
Study 28797270 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Marijuana Check-Up (TMCU) intervention
Number of subjects: 0
Study 28797270 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed technical assistance
Number of subjects: 0
Study 28797270 — intervention group
Group type: COMPARATOR
Intervention: Gold-standard technical assistance
Number of subjects: 0
Study 28797270 — intervention group
Group type: COMPARATOR
Intervention: Waitlist/control group
Number of subjects: 0
Study 28797293 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS intervention
Number of subjects: 18
Study 28797351 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 985
Study 28797353 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with next-generation self-expanding transcatheter heart valve (THV) system
Number of subjects: 1038
Study 28797458 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-C (nab-paclitaxel/cisplatin/5-FU + cetuximab)
Number of subjects: 60
Study 28797458 — intervention group
Group type: COMPARATOR
Intervention: APF (nab-paclitaxel/cisplatin/5-FU)
Number of subjects: 60
Study 28797458 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-C
Number of subjects: 60
Study 28797458 — intervention group
Group type: COMPARATOR
Intervention: APF
Number of subjects: 60
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy for cGVHD
Number of subjects: 227
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower NIH global severity scores
Number of subjects: 227
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lung scores
Number of subjects: 227
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Less extensive deep sclerosis (<37% body surface area)
Number of subjects: 227
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower patient- and clinician-reported 0 to 10 severity NIH scores
Number of subjects: 227
Study 28797782 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncyclosporine prophylaxis regimens
Number of subjects: 227
Study 28797911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-free biliary cannulation, sphincterotomy, and cholangioscopy for stone extraction
Number of subjects: 40
Study 28797911 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 40
Study 28797911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study 28798042 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 181
Study 28798091 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength training, duration not available.
Number of subjects: 0
Study 28798091 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessments related to quadriceps strength, details not available.
Number of subjects: 0
Study 28798090 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Number of subjects: 0
Study 28798986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod (0.5 mg/day for at least 2 weeks, increased to 1 mg/day)
Number of subjects: 167
Study 28799258 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 590
Study 28799258 — intervention group
Group type: COMPARATOR
Intervention: Persistent H. pylori infection
Number of subjects: 590
Study 28799258 — intervention group
Group type: COMPARATOR
Intervention: Serum ratio of PGI:PGII of three or less at the time of endoscopic submucosal dissection
Number of subjects: 590
Study 28799258 — intervention group
Group type: COMPARATOR
Intervention: Persistent decrease in mean serum ratio of PGI:PGII to 3 or less
Number of subjects: 590
Study 28800492 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone/prednisolone (AAP)
Number of subjects: 82
Study 28800492 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 82
Study 28800628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 80mg oral dose
Number of subjects: 990
Study 28801186 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide (12 4-week cycles of 150-200 mg/m²) with radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy)
Number of subjects: 745
Study 28801186 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy) alone
Number of subjects: 745
Study 28801338 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 77
Study 28801338 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated with rituximab)
Number of subjects: 77
Study 28801404 — intervention group
Group type: COMPARATOR
Intervention: Preoperative physical activity (active)
Number of subjects: 5733
Study 28801407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnoeic individuals
Number of subjects: 240
Study 28801407 — intervention group
Group type: COMPARATOR
Intervention: Non-dyspnoeic individuals
Number of subjects: 240
Study 28801417 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter (ONSD) sonography
Number of subjects: 0
Study 28801417 — intervention group
Group type: COMPARATOR
Intervention: CT scan, MRI, ICP monitor, lumbar puncture (LP)
Number of subjects: 0
Study 28801442 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention for environmental enteric dysfunction (EED)
Number of subjects: 3
Study 28801477 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 507
Study 28801477 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired renal function (eCCl <60 mL/min)
Number of subjects: 507
Study 28801477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both T2DM and eCCl <60 mL/min
Number of subjects: 507
Study 28801477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline (mild cognitive impairment or dementia)
Number of subjects: 507
Study 28801477 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM and lower eCCl
Number of subjects: 507
Study 28801537 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPLATZER Septal Occluder
Number of subjects: 1000
Study 28801539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 2010
Study 28801539 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2010
Study 28802168 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine (30µg)
Number of subjects: 220
Study 28802168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBV vaccine)
Number of subjects: 220
Study 28802255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym015, an antibody mixture composed of two humanized IgG
Number of subjects: 0
Study 28802755 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination in pneuCAP patients
Number of subjects: 60
Study 28802755 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination in otherCAP patients
Number of subjects: 60
Study 28802811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure threshold respiratory training (RT)
Number of subjects: 44
Study 28802811 — intervention group
Group type: COMPARATOR
Intervention: Untrained control subjects
Number of subjects: 44
Study 28803122 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet of rosuvastatin 20 mg/ezetimibe 10 mg
Number of subjects: 64
Study 28803122 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of rosuvastatin 20 mg and ezetimibe 10 mg
Number of subjects: 64
Study 28803351 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles
Number of subjects: 0
Study 28803351 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ixazomib with lenalidomide and dexamethasone (IRd)
Number of subjects: 0
Study 28803351 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib
Number of subjects: 0
Study 28803351 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ixazomib exposure
Number of subjects: 0
Study 28803351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib systemic exposure
Number of subjects: 0
Study 28803675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness center intervention (structured thrice weekly aerobic and resistance exercise program, supervised for the first 6 months)
Number of subjects: 154
Study 28803675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness center intervention
Number of subjects: 154
Study 28803675 — intervention group
Group type: COMPARATOR
Intervention: Home based physical activity group
Number of subjects: 154
Study 28804454 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy using a novel rehabilitation device
Number of subjects: 4
Study 28804864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 416
Study 28805662 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts) infused at doses of 0.2 × 10^8 to 2 × 10^8 CD30.CAR-Ts/m2
Number of subjects: 9
Study 28805662 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts)
Number of subjects: 9
Study 28806216 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas blocks
Number of subjects: 22434
Study 28806216 — intervention group
Group type: COMPARATOR
Intervention: Femoral blocks
Number of subjects: 22434
Study 28806373 — intervention group
Group type: EXPERIMENTAL
Intervention: H-PACT
Number of subjects: 3981
Study 28806373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3981
Study 28806373 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled
Number of subjects: 3981
Study 28806894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Courts (MHCs)
Number of subjects: 16129
Study 28806894 — intervention group
Group type: COMPARATOR
Intervention: Traditional criminal processing
Number of subjects: 16129
Study 28806957 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 1160
Study 28806957 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers analysis (k13, pfarps10, pffd, pfmdr2)
Number of subjects: 1160
Study 28806961 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine resistance (pfcrt K76T mutation)
Number of subjects: 130
Study 28806961 — intervention group
Group type: EXPERIMENTAL
Intervention: pfmdr1 N86Y mutation
Number of subjects: 130
Study 28806961 — intervention group
Group type: EXPERIMENTAL
Intervention: k13 propeller region mutations
Number of subjects: 130
Study 28807017 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally applied metronidazole
Number of subjects: 0
Study 28807017 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 0
Study 28807017 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0
Study 28807118 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma combined with hyaluronic acid
Number of subjects: 0
Study 28807118 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28807382 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1200
Study 28807448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D shear wave elastography (2-D-SWE)
Number of subjects: 121
Study 28807914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone exposure
Number of subjects: 122
Study 28808182 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH)
Number of subjects: 0
Study 28808182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28808360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU anti-factor Xa, subcutaneous injection once daily)
Number of subjects: 100
Study 28808360 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg, subcutaneous injection once daily)
Number of subjects: 100
Study 28808360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 100
Study 28808443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor) for 1 week
Number of subjects: 27
Study 28808480 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy with modified EPIC regimen (etoposide, prednisolone, ifosfamide, cisplatin), median 3 cycles (range 1-6)
Number of subjects: 21
Study 28809387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge
Number of subjects: 80
Study 28809387 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy with biopsy
Number of subjects: 80
Study 28810177 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic medications (SGAs)
Number of subjects: 303
Study 28810177 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed women with psychiatric conditions
Number of subjects: 303
Study 28810418 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored cardiovascular disease prevention program
Number of subjects: 0
Study 28810801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented papaya preparation (FPP)
Number of subjects: 0
Study 28810801 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 0
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg + Bevacizumab 7.5 mg/kg (DL1)
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg + Bevacizumab 7.5 mg/kg (DL2)
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg + Bevacizumab 10 mg/kg (DL3)
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg + Bevacizumab 10 mg/kg (DL4)
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (400 mg and 600 mg) pharmacokinetics
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 25
Study 28810837 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity profile
Number of subjects: 25
Study 28810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) - beta blockers (80.9% in previously diagnosed AF, 71.0% in newly diagnosed AF), calcium channel antagonists (24.0% in newly diagnosed AF).
Number of subjects: 1013
Study 28810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) - class I (11.4%) and class III (9.1%) AADs.
Number of subjects: 1013
Study 28810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers as rate control therapy.
Number of subjects: 1013
Study 28810925 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical IPP with melphalan 30 mg/m²
Number of subjects: 10
Study 28810925 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous IPP with melphalan 30 mg/m²
Number of subjects: 10
Study 28812042 — intervention group
Group type: EXPERIMENTAL
Intervention: LaserACE procedure
Number of subjects: 26
Study 28812172 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (ADM)
Number of subjects: 22
Study 28812175 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 28812175 — intervention group
Group type: COMPARATOR
Intervention: Emergency appendectomy
Number of subjects: 0
Study 28813164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity.
Number of subjects: 24
Study 28813164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 24
Study 28814281 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation hormone-therapy (NGHT)
Number of subjects: 134
Study 28814281 — intervention group
Group type: COMPARATOR
Intervention: First generation androgen deprivation therapy (Control)
Number of subjects: 134
Study 28814281 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (NGHT)
Number of subjects: 134